Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Methanol”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed1991

Structure of aqua-hexakis(mu 2-benzoato)-bis(methanol)-mu 3-oxo-triiron(III) benzoate ethanol methanol solvate.

[Fe3(O)(C7H5O2)6(CH3OH)2(H2O)]-[C7H5O2]-C2H5OH-CH3OH (1/1/1), Mr = 1191.56, triclinic, P1-, a = 11.591 (3), b = 13.308 (2), c = 20.154 (3) A, alpha = 96.910 (12), beta = 96.95 (2), gamma = 114.10 (2) degrees, V = 2767.1 (9) A3, Z = 2, Dx = 1.43 g cm-3, mu = 8.471 cm-1, Mo K alpha radiation, lambda = 0.7107 A, F(000) = 1234, T = 198 K, R = 0.0522 for 6252 reflections [Fo greater than or equal to 4 sigma (Fo)]. The complex has nearly D3h symmetry with two coordinated CH3OH molecules and one coordinated H2O molecule. The coordination around the Fe atoms is essentially octahedral. Each Fe atom lies slightly out of the plane of the O atoms of the bridging benzoates and is directed towards the mu 3-O atom. The average Fe--O distances are 1.907 (2) A for the mu 3-O atom and 2.010 (1) A for the benzoate O atoms.

Benzoates↗
PubMed1973

Prophylactic activity of a phenanthrene methanol (WR 33063) and a quinoline methanol (WR 30090) in human malaria.

WR 33063 (3-bromo-10-[alpha-hydroxy-beta-(n, n-diheptylamino)ethyl]-phenanthrene hydrochloride) and WR 30090 (6,8-dichloro-2,3,4-dichlorphenyl-di-n-butylaminoethyl-4- quinolinemethanol hydrochloride) were tested for suppressive prophylactic effect on induced malaria in nonimmune volunteers living in an area where malaria is not naturally transmitted. Doses of 800 mg of WR 33063 and 690 or 460 mg of WR 30090 were given at weekly intervals to men exposed on the day of the first dose to mosquitoes heavily infected with chloroquine- and pyrimethamine-resistant strains of Plasmodium falciparum. WR 33063 did not interfere with early development of infection, but WR 30090 given for 8 weeks provided suppressive cures in 20 of 26 men. P. vivax infections similarly induced broke through WR 30090 treatment in 4 of 15 men, and most of the remainder experienced malaria after completion of the prophylactic course. No side effects of treatment were observed.

Antimalarials↗